Functional relevance of antiemetic control

Autor:	M. Elmer, A. R. Martin, J. D. Pearson, B. Cai, Steven M. Grunberg, Alexandra D. Carides, Sant P. Chawla, C. Schmidt, Kevin J. Horgan
Rok vydání:	2003
Předmět:	Cancer Research medicine.drug_class Nausea business.industry law.invention Ondansetron Regimen Oncology Randomized controlled trial law Anesthesia medicine Vomiting Antiemetic medicine.symptom business Dexamethasone Aprepitant medicine.drug
Zdroj:	European Journal of Cancer. 39:1395-1401
ISSN:	0959-8049
Popis:	Little information exists on the functional impact of effective antiemetic protection. In the present study, the Functional Living Index-Emesis (FLIE), was used to assess patient-reported impact of chemotherapy-induced nausea and vomiting (CINV) after administration of a new NK-1 receptor antagonist (aprepitant). Cisplatin-treated patients in a double-blind randomised trial received either aprepitant+dexamethasone+ondansetron on day 1 and aprepitant+dexamethasone on days 2-5 or standard antiemetic therapy (dexamethasone and ondansetron on day 1 and dexamethasone on days 2-5). Emetic events, nausea ratings and rescue medications were recorded in a 5-day diary and the FLIE was completed on day 6. Compared with standard therapy, significantly more patients treated with the high dose aprepitant regimen achieved a Complete Response (71 vs 44%, P
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::8241f56ecced90b7981aca8b374dbbca https://doi.org/10.1016/s0959-8049(03)00299-5 Zobrazit plný text záznamu Full Text from ScienceDirect